Clinical Trial Update: Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing HX575 (Hexal AG) to ERYPO® for anemia in hemodialysis patients has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia

Drugs mentioned

• HX575 (epoetin alfa)

Snippet

Sponsor: Sandoz | Conditions: Anemia | Phase 3 | Status: COMPLETED | Results posted: 2017-08-02